Mutation in RFC1 gene is likely to be common cause of late-onset ataxia

A mutation in gene found to be responsible for CANVAS, a specific form of late onset ataxia, is likely to also be responsible for forms of late onset ataxia with unknown causes. Read more

Real-time audio-biofeedback (ABF) shown to improve stability in degenerative cerebellar ataxia

A group of researchers from Germany have found that real-time audio bio-feedback improves stability in degenerative cerebellar ataxia. Read more

Preliminary evidence suggests that speech treatment could improve difficulty speaking in ARSACS

A recently published study has demonstrated that intensive home-based speech therapy can improve dysarthria (difficulty speaking) in autosomal recessive spastic ataxia Charlevoix-Saguenay (ARSACS). Read more

AMRC Impact Report

The AMRC Impact Report highlights the concrete ways that medical research charities make a difference to people and society through the research they fund Read more

New initiative for rare diseases launched by Finnish pharmaceutical company

The 'New Modalities Ecosystem’, launched in 2018 by the Finnish pharmaceutical company Orion, aims to exploit Finnish expertise to deliver new treatments and technologies for rare diseases. Read more

Effects of physiotherapy in patients with spinocerebellar ataxia type 7

A recent study investigating the effect of investigating the effect of physiotherapy on patients with spinocerebellar ataxia type 7 (SCA7) has found that it to significantly improve symptoms. Read more

Euro-ataxia annual meeting

Ataxia UK's Head of Research Julie Greenfield reports on the 2018 Euro-ataxia annual conference held in Frankfurt. Read more

EFACTS reports most common 'non-ataxia' symptoms in FA

The ongoing European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) study, part-funded by Ataxia UK has released a report evaluating the clinical variability in Friedreich’s ataxia (FA) symptoms. Read more

Friedreich’s ataxia may cause greater susceptibility to skin damage by UVA rays

Experiments in the laboratory using skin cells taken from people with Friedreich’s ataxia have shown that these cells may be more susceptible to damage caused by certain sun rays. Read more

Minoryx therapeutics announces new trial in Friedreich’s ataxia in a few European countries

Ataxia UK has been talking with Minoryx therapeutics, a company focusing on developing new drugs for rare conditions, and we are delighted with this new trial being announced. Read more

Ataxia UK medical guidelines published in peer-reviewed journal

We are delighted that on 20 February 2019 the Ataxia UK Medical Guidelines were published in the Orphanet Journal of Rare Diseases. Read more

Non-invasive eye exam found to predict disease severity in Friedreich’s ataxia

A study has found that a rapid, non-invasive eye exam could potentially be used as a tool for assessing Friedreich's ataxia patients and as a biomarker in clinical trials. Read more

Increasing levels of a protein in FA may be potential future therapy

Experiments performed in mice and in cells taken from Friedreich's ataxia (FA) patients reveal a protein called 'GRP75' might be an effective future treatment approach. Read more

Results presented from patient communications survey

The results of the patient communications survey conducted at the 2018 Ataxia UK conference were presented in London by Ataxia UK partners Costello Medical. Read more

HIV treatment identified as potential future therapy for FA

Study finds anti-viral drug leads to decrease in frataxin levels and may be a potential future candidate for treating Friedreich's ataxia (FA). Read more

SCA drug trial to begin in America

Second trial investigating troriluzole in spinocerebellar ataxia announced by Biohaven pharmaceuticals to commence at the end of January. Read more

Study discovers 3 potential blood based biomarkers for FA

Results from a study conducted at the London Ataxia Centre have shown that 3 proteins which may represent new biomarkers in Friedreich's ataxia (FA). Read more

Glut 1 deficiency syndrome trial announces negative results

A potential therapy for Glucose transporter 1 deficiency syndrome (Glut1 DS) has produced negative results in phase 3 of its clinical trial. Read more

Results published from part 1 of Friedreich's ataxia drug trial

Results from MOXIe study reveal potential therapy for Friedreich's ataxia, omaveloxolone, is well tolerated. Read more

International Ataxia Research Conference (IARC) 2019 - Save the date!

Ataxia UK, GoFAR, FARA US and FARA Australia are pleased to announce the date of 3rd International Ataxia Research Conference. Read more